Allakos (ALLK) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALLK shares.
View ALLK analyst ratings or view top-rated stocks.

6 equities research analysts have issued 1-year target prices for Allakos' shares. Their ALLK share price forecasts range from $7.00 to $22.00. On average, they expect the company's share price to reach $13.60 in the next twelve months. This suggests a possible upside of 159.0% from the stock's current price.
View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts.

Allakos' stock was trading at $8.42 on January 1st, 2023. Since then, ALLK stock has decreased by 37.6% and is now trading at $5.25.
View the best growth stocks for 2023 here.

Allakos saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 4,310,000 shares, a decrease of 12.6% from the April 30th total of 4,930,000 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is currently 3.7 days. Approximately 8.3% of the shares of the stock are sold short.
View Allakos' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ALLK earnings forecast.

Allakos Inc. (NASDAQ:ALLK) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49).

ETFs with the largest weight of Allakos (NASDAQ:ALLK) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA SmallCap Momentum ETF (DWAS), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ProShares Ultra Nasdaq Biotechnology (BIB), BlackRock Future Health ETF (BMED),

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

(ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Allakos' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (7.00%), Logos Global Management LP (6.40%), State Street Corp (4.42%), BlackRock Inc. (2.95%), Commodore Capital LP (2.20%) and Federated Hermes Inc. (1.76%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends.

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLK stock can currently be purchased for approximately $5.25.

Allakos (NASDAQ:ALLK) has a market capitalization of $454.44 million. The company earns $-319,950,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

The company employs 192 workers across the globe.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.